Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of sex hormone administration on marrow and visceral adiposity in transgender persons
2017-003072-31Phase 4Completed
- Sponsor
- VU University Medical Center
- Start
- Mar 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of anastrozole and triptorelin in gender dysphoria (GD), sponsored by VU University Medical Center. Primary endpoint: Change in vertebral bone marrow fat fraction. Started Mar 2018; status: completed.
02
Drugs
anastrozoletriptorelin
03
Conditions
gender dysphoria (GD)
Beyond the preview
Go deeper on 2017-003072-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003072-31.